gatifloxacin has been researched along with Bacillus anthracis Infection in 4 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the fluoroquinolones gatifloxacin and moxifloxacin with ciprofloxacin for post-exposure prophylaxis of systemic anthrax in a BALB/c mouse model." | 3.72 | Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. ( Brooks, TJ; Lever, MS; Sefton, AM; Simpson, AJ; Steward, J, 2004) |
| "Gatifloxacin was administered at 6- or 8-h intervals beginning 24 h postchallenge for 21 days, and dosing was designed to produce profiles mimicking fractionated concentration-time profiles for humans." | 1.34 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. ( Ambrose, PG; Bhavnani, SM; Craig, WA; Drusano, GL; Forrest, A; Heine, HS; Rubino, CM, 2007) |
| "Levofloxacin was bactericidal at 1 x MIC after 24 h and at 4 x MIC after 12 h, and gatifloxacin was bactericidal at 2 x MIC after 24 h and at 8 x MIC after 12 h." | 1.31 | Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates. ( De Vecchi, E; Drago, L; Gismondo, MR; Lombardi, A; Nicola, L; Valli, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrose, PG | 1 |
| Forrest, A | 1 |
| Craig, WA | 1 |
| Rubino, CM | 1 |
| Bhavnani, SM | 1 |
| Drusano, GL | 1 |
| Heine, HS | 1 |
| Drago, L | 1 |
| De Vecchi, E | 1 |
| Lombardi, A | 1 |
| Nicola, L | 1 |
| Valli, M | 1 |
| Gismondo, MR | 1 |
| Esel, D | 1 |
| Doganay, M | 1 |
| Sumerkan, B | 1 |
| Steward, J | 1 |
| Lever, MS | 1 |
| Simpson, AJ | 1 |
| Sefton, AM | 1 |
| Brooks, TJ | 1 |
4 other studies available for gatifloxacin and Bacillus anthracis Infection
| Article | Year |
|---|---|
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Topics: Air Microbiology; Animals; Anthrax; Anti-Infective Agents; Area Under Curve; Bacillus anthracis; Dis | 2007 |
Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Fluoroquinolones; Gatiflo | 2002 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bac | 2003 |
Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Topics: Animals; Anthrax; Anti-Infective Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; Female; F | 2004 |